Design Therapeutics/$DSGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Design Therapeutics
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Ticker
$DSGN
Sector
Primary listing
Employees
57
Headquarters
Website
DSGN Metrics
BasicAdvanced
$315M
-
-$1.12
1.58
-
Price and volume
Market cap
$315M
Beta
1.58
52-week high
$7.59
52-week low
$2.60
Average daily volume
207K
Financial strength
Current ratio
25.128
Quick ratio
24.726
Long term debt to equity
0.517
Total debt to equity
0.517
Profitability
EBITDA (TTM)
-74.314
Management effectiveness
Return on assets (TTM)
-19.02%
Return on equity (TTM)
-26.77%
Valuation
Price to book
1.48
Price to tangible book (TTM)
1.48
Price to free cash flow (TTM)
-6.178
Free cash flow yield (TTM)
-16.19%
Free cash flow per share (TTM)
-0.895
Growth
Earnings per share change (TTM)
24.65%
3-year earnings per share growth (CAGR)
7.04%
What the Analysts think about DSGN
Analyst ratings (Buy, Hold, Sell) for Design Therapeutics stock.
Bulls say / Bears say
Design Therapeutics has initiated dosing of the first Friedreich ataxia patient in its RESTORE-FA Phase 1/2 trial of DT-216P2, demonstrating clinical momentum for its lead program in ex-U.S. sites. (Investing.com)
DT-168’s Phase 1 SAD/MAD trial in healthy volunteers showed it was well-tolerated with no serious or ocular adverse events, supporting the planned Phase 2 biomarker trial in Fuchs endothelial corneal dystrophy patients in H2 2025. (Nasdaq)
As of June 30, 2025, Design Therapeutics held $216.3 million in cash and securities, providing a multi-year runway to fund its GeneTAC™ programs without near-term dilution. (Reuters)
The FDA has placed a clinical hold on the U.S. IND application for DT-216P2, delaying expansion of the RESTORE-FA trial into U.S. sites until outstanding nonclinical deficiencies are addressed. (Reuters)
Design Therapeutics reported a net loss of $19.1 million and R&D expenses of $15.7 million in Q2 2025, highlighting significant cash burn and persistent operating losses. (Reuters)
Analysts at RBC Capital warn that without proof-of-concept efficacy data—expected only in 2026 for its lead FA and FECD programs—the stock may lack near-term catalysts and underperform until pivotal readouts. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2025.
DSGN Financial Performance
Revenues and expenses
DSGN Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Design Therapeutics stock?
Design Therapeutics (DSGN) has a market cap of $315M as of October 24, 2025.
What is the P/E ratio for Design Therapeutics stock?
The price to earnings (P/E) ratio for Design Therapeutics (DSGN) stock is 0 as of October 24, 2025.
Does Design Therapeutics stock pay dividends?
No, Design Therapeutics (DSGN) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Design Therapeutics dividend payment date?
Design Therapeutics (DSGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Design Therapeutics?
Design Therapeutics (DSGN) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.